Speaker
Description
Background: Emerging aetiological evidence has broadened the spectrum of diseases attributable to Epstein–Barr virus (EBV). Quantifying productivity losses from EBV-associated premature mortality can inform investment in research and prevention.
Methods: We estimated productivity losses from premature mortality attributable to EBV across seven diseases in 185 countries and territories in 2024: Burkitt lymphoma, diffuse large B-cell lymphoma, extranodal NK/T-cell lymphoma of nasal type, Hodgkin lymphoma, nasopharyngeal carcinoma (NPC), gastric cancer, and multiple sclerosis (MS). Years of productive life lost (YPLL) were calculated using GLOBOCAN 2024, Cancer Incidence in Five Continents, Global Burden of Disease Study 2023, and WHO life tables, defining premature deaths as those occurring before age 65. EBV population attributable fractions were primarily obtained from published studies. Paid and unpaid productivity losses were valued using human capital and opportunity cost approaches, respectively, with economic, labour, and unpaid activity data from international databases.
Results: In 2024, an estimated 68,854 premature deaths were attributable to EBV, resulting in approximately 0.9 million YPLL. Total productivity losses amounted to US$13.8 billion, equivalent to 0.013% of global GDP. MS (US$4.8 billion) and NPC (US$4.3 billion) were the largest contributors. MS predominated in Europe, North America, and Australia/New Zealand, whereas NPC contributed substantially in Eastern and South-Eastern Asia. Losses were approximately twice as high in males as in females.
Conclusions: EBV-associated premature mortality imposes substantial societal costs through lost paid and unpaid productivity. These findings support greater investment in EBV research, prevention, and control, with priorities informed by regional differences in the contributions of individual diseases.